Ironwood Pharmaceuticals：一项试验决定其是属于“低价股”还是“彻底崩盘” (NASDAQ:IRWD)
· seekingalpha.com
Ironwood Pharmaceuticals 的交易价格较其经风险调整的分类加总估值 (SOTP) 折价 40%，其价值主要由 LINZESS 和 apraglutide 支撑。点击此处阅读更多关于 IRWD 股票的信息。
Ironwood Pharmaceuticals, Inc. ( IRWD ) is currently priced at a 40% discount to the risk-adjusted sum-of-the-parts value. In this article, I break down the val...